Drugs Made In America Acquisition Corp. ( (DMAA) ) has released a notification of late filing.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Drugs Made In America Acquisition Corp. has announced a delay in filing its Form 10-Q (Quarter Report) for the financial period ending March 31, 2025. The delay is primarily due to the inability to complete financial statements in time to obtain necessary reviews and signatures. The company anticipates that the report will be filed within five calendar days following the prescribed due date. There are no expected significant changes in financial results from the previous year, and the company is committed to maintaining compliance with filing requirements. The notification was signed by Lynn Stockwell, the Chief Executive Officer.
More about Drugs Made In America Acquisition Corp.
Average Trading Volume: 190,807
Current Market Cap: $235.6M
For an in-depth examination of DMAA stock, go to TipRanks’ Stock Analysis page.